Cargando…

Efficacy and safety of tolvaptan in patients with malignant ascites: a phase 2, multicenter, open-label, dose-escalation study

OBJECTIVE: This phase 2 study examined the efficacy and safety of tolvaptan, an aquaretic drug, in the treatment of ascites associated with cancer. METHODS: In the dose-escalation phase, oral tolvaptan was initiated at a dose of 3.75 mg/day, and the dose was increased daily to 7.5, 15 and 30 mg/day....

Descripción completa

Detalles Bibliográficos
Autores principales:	Kudo, Toshihiro, Murai, Yoshiyuki, Kojima, Yoshitsugu, Uehara, Kenji, Satoh, Taroh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7937426/ https://www.ncbi.nlm.nih.gov/pubmed/33173939 http://dx.doi.org/10.1093/jjco/hyaa196

Ejemplares similares

Tolvaptan for the Treatment of Refractory Ascites
por: Kurosaki, Masayuki, et al.
Publicado: (2016)

Cases with Refractory Ascites and a Delayed Response to Tolvaptan
por: Hagiwara, Satoru, et al.
Publicado: (2016)

Cell-free and Concentrated Ascites Reinfusion Therapy for Refractory Ascites in Cirrhosis in Post-marketing Surveillance and the Role of Tolvaptan
por: Iwasa, Motoh, et al.
Publicado: (2019)

Prediction factors of tolvaptan effectiveness in patients with refractory ascites complicated with hepatocellular carcinoma
por: Imai, Michitaka, et al.
Publicado: (2020)

Impact of continued administration of tolvaptan on cirrhotic patients with ascites
por: Kogiso, Tomomi, et al.
Publicado: (2018)

Management of Cirrhotic Ascites under the Add-on Administration of Tolvaptan
por: Adachi, Takuya, et al.
Publicado: (2021)

Tolvaptan treatment improves survival of cirrhotic patients with ascites and hyponatremia
por: Wang, Shuzhen, et al.
Publicado: (2018)

Re-response to tolvaptan after furosemide dose reduction in a patient with refractory ascites
por: Goto, Atsushi, et al.
Publicado: (2014)

Early Administration of Tolvaptan Can Improve Survival in Patients with Cirrhotic Ascites
por: Hosui, Atsushi, et al.
Publicado: (2021)

Cisterna chyli as an optimal marker of tolvaptan response in severe cirrhotic ascites
por: Hirooka, Masashi, et al.
Publicado: (2022)

Tunnelled Peritoneal Catheter for Malignant Ascites—An Open-Label, Prospective, Observational Trial
por: Petzold, Golo, et al.
Publicado: (2021)

The Outcome of Cirrhotic Patients with Ascites Is Improved by the Normalization of the Serum Sodium Level by Tolvaptan
por: Kogiso, Tomomi, et al.
Publicado: (2017)

PB2349: A PHASE 1, OPEN-LABEL, MULTICENTER, DOSE-ESCALATION STUDY OF SGR-1505 AS MONOTHERAPY IN SUBJECTS WITH MATURE B-CELL MALIGNANCIES
por: Olszewski, Adam, et al.
Publicado: (2023)

Phase I, multicenter, open‐label, dose‐escalation study of sonidegib in Asian patients with advanced solid tumors
por: Minami, Hironobu, et al.
Publicado: (2016)

Serum Copeptin and Zinc-α2-glycoprotein Levels Are Novel Biomarkers of Tolvaptan Treatment in Decompensated Cirrhotic Patients with Ascites
por: Shigefuku, Ryuta, et al.
Publicado: (2021)

Risk and protective factors of acute kidney injury in decompensated cirrhotic patients with ascites on tolvaptan
por: Kogiso, Tomomi, et al.
Publicado: (2021)

Survival in infants treated with sebelipase Alfa for lysosomal acid lipase deficiency: an open-label, multicenter, dose-escalation study
por: Jones, Simon A., et al.
Publicado: (2017)

A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis
por: Verstovsek, S, et al.
Publicado: (2017)

Impaired Renal Function May Not Negate the Efficacy of Tolvaptan in the Treatment of Cirrhotic Patients with Refractory Ascites
por: Arase, Yoshitaka, et al.
Publicado: (2018)

Association between the Serum Sodium Levels and the Response to Tolvaptan in Liver Cirrhosis Patients with Ascites and Hyponatremia
por: Hayashi, Manabu, et al.
Publicado: (2018)

MON-282 Treatment of Hyperprolactinemia with Ropinirole: An Open-Label Dose Escalation Study
por: Tsang, Amanda, et al.
Publicado: (2020)

Tolvaptan
por: Rangarajan, Bharath, et al.
Publicado: (2014)

Clinical implications with tolvaptan on monitored bioimpedance-defined fluid status in patients with cirrhotic ascites: an observational study
por: Shiba, Shunsuke, et al.
Publicado: (2020)

Phase I dose-escalation study of the c-Met tyrosine kinase inhibitor SAR125844 in Asian patients with advanced solid tumors, including patients with MET-amplified gastric cancer
por: Shitara, Kohei, et al.
Publicado: (2017)

A Prospective, Multicenter, Open-Label Study of Dose Escalation Therapy in Male Patients With Nocturia Refractory to 0.2-mg Tamsulosin Monotherapy
por: Yu, Ho Song, et al.
Publicado: (2019)

Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: part 2 of the open-label, multicenter, dose-escalation phase Ib study (PAVO)
por: San-Miguel, Jesus, et al.
Publicado: (2020)

First reports of clinical effects of transjugular intrahepatic portosystemic shunt in four patients with cirrhotic ascites refractory to tolvaptan
por: Tsuruya, Kota, et al.
Publicado: (2023)

Phase I, multicenter, dose‐escalation study of avadomide in adult Japanese patients with advanced malignancies
por: Hatake, Kiyohiko, et al.
Publicado: (2020)

Zandelisib (ME-401) in Japanese patients with relapsed or refractory indolent non-Hodgkin’s lymphoma: an open-label, multicenter, dose-escalation phase 1 study
por: Goto, Hideki, et al.
Publicado: (2022)

Multicenter, Open-Label, Phase I Study of DSP-7888 Dosing Emulsion in Patients with Advanced Malignancies
por: Spira, Alexander, et al.
Publicado: (2021)

Practical guidance for the evaluation of disease progression and the decision to change treatment in patients with advanced gastric cancer receiving chemotherapy
por: Iwasa, Satoru, et al.
Publicado: (2020)

A phase I/II multicenter, open-label, dose escalation and randomized trial of BI 836858 in patients with low- or intermediate-1-risk myelodysplastic syndrome
por: Komrokji, Rami S., et al.
Publicado: (2022)

Treatment of active lupus nephritis with the novel immunosuppressant 15-deoxyspergualin: an open-label dose escalation study
por: Lorenz, Hanns-Martin, et al.
Publicado: (2011)

Tolvaptan- and Tolvaptan-Metabolite-Responsive T Cells in Patients with Drug-Induced Liver Injury
por: Gibson, Andrew, et al.
Publicado: (2020)

Open‐Label, Dose‐Escalation, Phase 1 Study of Safety and Single and Multiple‐Dose Pharmacokinetics of Dichlorphenamide in Healthy Volunteers
por: Cohen, Fredric
Publicado: (2018)

Clinical Validation of a Multiplex Kit for RAS Mutations in Colorectal Cancer: Results of the RASKET (RAS KEy Testing) Prospective, Multicenter Study
por: Yoshino, Takayuki, et al.
Publicado: (2015)

Dose-escalation of human anti-interferon-α receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study
por: Goldberg, Avram, et al.
Publicado: (2014)

Long-Term Tolvaptan Treatment in Refractory Heart Failure
por: Imamura, Teruhiko, et al.
Publicado: (2019)

Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial
por: Torres, Vicente E, et al.
Publicado: (2018)

P1121: TAKEAIM LYMPHOMA- AN OPEN-LABEL, DOSE ESCALATION AND EXPANSION TRIAL OF EMAVUSERTIB (CA-4948) IN COMBINATION WITH IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES
por: Joffe, E., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_lbcplqkd000p702ka2gno2rqm1